Poor Metabolic Health Associated With Increased Risk for Colorectal Cancer
Among postmenopausal women who were normal weight, those who were metabolically unhealthy had a significantly increased risk for colorectal cancer compared with those who were metabolically healthy, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Metabolic health is often assessed by measuring waist circumference, blood pressure, and levels of triglycerides, glucose, and high-density lipoprotein cholesterol (HDL-C, so-called “good” cholesterol) in the blood. People have metabolic syndrome if they have three or more of the following: elevated waist circumference, elevated blood pressure, elevated levels of triglycerides, elevated levels of glucose, and low levels of HDL-C. In this study, people were considered metabolically unhealthy if they had two or more of those factors excluding elevated waist circumference.
“Even though poor metabolic health is usually associated with obesity, 30 percent of normal-weight adults are believed to be metabolically unhealthy worldwide,” said Xiaoyun Liang, MD, PhD, an associate professor at Beijing Normal University in China.
“Our finding that normal-weight U.S. women who are metabolically unhealthy have an increased risk of colorectal cancer compared with those who are metabolically healthy highlights how important it is for women to be aware of their metabolic health status, which can be assessed using standard clinical tests,” continued Liang. “Colorectal cancer is the third most commonly diagnosed cancer for women in the United States. Recognition that normal-weight women who are metabolically unhealthy may have an increased risk for colorectal cancer could result in more timely use of preventive interventions and reduce the burden of this deadly disease.”
For this study, Liang and colleagues used data from 5,068 postmenopausal women enrolled in the Women’s Health Initiative. All the women were classed as normal weight based on having a body mass index (BMI) from 18.5 kg/m2 to <25 kg/m2; 33.7 percent of them were metabolically unhealthy.
During a mean follow-up time of 14.3 years, 64 of the 3,358 women who were classed as metabolically healthy were diagnosed with colorectal cancer and 50 of the 1,710 metabolically unhealthy women. After adjusting for numerous factors that affect colorectal cancer risk, the researchers calculated that women who were metabolically unhealthy had a 49 percent increased risk for colorectal cancer relative to those who were metabolically healthy.
The researchers also found that women with metabolic syndrome had a more than two-fold higher risk for colorectal cancer relative to those who were metabolically healthy. According to Liang, the study had two main limitations. First, BMI and components of metabolic health were measured only at the time of enrolment in the Women’s Health Initiative and possible changes over time could not be considered in the analysis. Second, the study population can be generalized only to postmenopausal women and not men or younger women.
Liang, X., Margolis, K. L., Hendryx, M., Rohan, T. E., Groessl, E. J., Thomson, C. A., Luo, J. (2017). Metabolic Phenotype and risk of Colorectal cancer in normal-weight Postmenopausal women. Cancer Epidemiology Biomarkers & Prevention. doi:10.1158/1055-9965.epi-16-0761
This article has been republished from materials provided by the American Association for Cancer Research. Note: material may have been edited for length and content. For further information, please contact the cited source.
Bioinformatics to Help Understand Intrinsically Disordered ProteinsNews
Over the last several decades, scientists have sequenced 85 million unique proteins, structured and unstructured alike, but still don’t know what the vast majority of these proteins do.READ MORE
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Comments | 0 ADD COMMENT
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018